The only biomarker so far used in clinical practice is carcinoembryonic antigen (CEA), but its value as an isolated screening and prognostic marker is limited and it is currently recommended as a supplement approach in monitoring CRC recurrence [8,9,10,11,12]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.